This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal cancer, and to explore the value and implications of radiotherapy omission in this setting.
The patient voluntarily consents to participate in this study, demonstrates good compliance, is able to meet the trial requirements for observation and follow-up, and has signed the informed consent form;
Age between 18 and 75 years, inclusive, regardless of gender (at the time of signing the informed consent);
ECOG Performance Status (PS) score of 0 or 1;
Expected survival time ≥12 weeks;
Clinical stage cT4b and low rectal cancer (tumor located less than 5 cm from the anal verge);
Prior rectal cancer surgery before enrollment, excluding stoma procedures;
History of malignancy, except for cured carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, or early-stage thyroid cancer;
Severe hypersensitivity or allergic reactions to humanized antibodies or fusion proteins in the past;